1. Home
  2. AMRN vs AGEN Comparison

AMRN vs AGEN Comparison

Compare AMRN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amarin Corporation plc

AMRN

Amarin Corporation plc

N/A

Current Price

$11.68

Market Cap

287.9M

Sector

Health Care

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$7.24

Market Cap

335.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMRN
AGEN
Founded
1989
1994
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
287.9M
335.6M
IPO Year
1998
1999

Fundamental Metrics

Financial Performance
Metric
AMRN
AGEN
Price
$11.68
$7.24
Analyst Decision
Strong Sell
Strong Buy
Analyst Count
2
3
Target Price
$12.50
★ $26.33
AVG Volume (30 Days)
73.3K
★ 736.2K
Earning Date
10-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
55.00
★ 100.00
EPS
N/A
★ 0.60
Revenue
★ $181,104,000.00
$42,877,086.00
Revenue This Year
N/A
$7.68
Revenue Next Year
$3.11
N/A
P/E Ratio
★ N/A
$11.67
Revenue Growth
39.22
★ 89.95
52 Week Low
$11.25
$2.71
52 Week High
$17.31
$10.19

Technical Indicators

Market Signals
Indicator
AMRN
AGEN
Relative Strength Index (RSI) 40.58 51.24
Support Level N/A $6.34
Resistance Level $15.34 $7.30
Average True Range (ATR) 0.50 0.47
MACD 0.01 0.10
Stochastic Oscillator 12.29 64.29

Price Performance

Historical Comparison
AMRN
AGEN

About AMRN Amarin Corporation plc

Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: